# A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.

> **NCT07729033** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Advanced Biliary Tract Cancers

## Interventions

- **DRUG:** Sacituzumab tirumotecan combined with envafolimab

## Key facts

- **NCT ID:** NCT07729033
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-12
- **Final completion:** 2028-07
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729033, "A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*